Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Riluzole is a primary treatment for ALS, offering modest survival benefits.
• The precise duration and mechanisms of riluzole's neuroprotective effects require further investigation.

Purpose of the Study:

• To longitudinally assess the effects of riluzole on cortical and peripheral nerve function in ALS patients.
• To determine the time course of riluzole's impact on neuronal excitability.
• To correlate functional changes with riluzole's known mechanisms of action.

Main Methods:

• Longitudinal study involving 19 sporadic ALS patients and 31 healthy controls.
• Assessment of cortical excitability using threshold tracking transcranial magnetic stimulation (TMS).
• Evaluation of peripheral nerve function through excitability studies at baseline, 4, 8, and 12 weeks post-riluzole initiation.

Main Results:

• Baseline ALS patients exhibited cortical hyperexcitability, evidenced by reduced short interval intracortical inhibition (SICI) and cortical silent period duration.
• Riluzole therapy increased SICI at 4 and 8 weeks, indicating a reduction in cortical hyperexcitability.
• Peripheral nerve studies revealed transient increases in the relative refractory period and superexcitability at 4 weeks, returning to baseline by 8 weeks.

Conclusions:

• Riluzole exerts transient modulatory effects on both cortical and axonal hyperexcitability in ALS patients.
• These temporary functional changes may underlie the modest clinical efficacy observed with riluzole treatment.
• Further research is needed to explore strategies for prolonging riluzole's therapeutic effects.